ClinicalTrials.gg
CompletedNCT00241449Updated Jun 6, 2012

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

A Phase 3 interventional study of Fulvestrant and Tamoxifen in Breast Cancer and Metastasis, sponsored by AstraZeneca. Completed at 139 sites in 26 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2012-06-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
54th of 94
51 · median 71
Started
1998
the only one that year
Phase 3
21 of 95
3 open now
Registered
14th of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 54th largest by enrollment of the 94 interventional ones that give a count, is the only one that started in 1998, is one of 21 in phase 3, and was the 14th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.

03

Conditions studied

  • Breast Cancer
  • Metastasis

Keywords

  • Locally advanced breast cancer or metastatic breast cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmation of breast cancer. Evidence of breast cancer that is not considered amenable to curative treatment.

women. Written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with hormonal therapy unless that therapy was tamoxifen for adjuvant breast cancer. The use of tamoxifen must have ceased at least one year before this study.

Previous treatment with Faslodex. Any existing serious disease, illness, or condition that will prevent participation or compliance with the study procedures.

Treatment with an or non-approved drug within one month of then start of the study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    1

    Tamoxifen

    Drug: Tamoxifen

  • Experimental
    2

    Fulvestrant

    Drug: Fulvestrant

Interventions

  • intramuscular injection 250 mg

    Also known as: Faslodex, ZD9238

  • 20 mg oral tablet

    Also known as: Nolvadex

06

What researchers measure

Primary outcomes

  1. Time to disease progression (TTP)

    It is considered that these results indicate that adequate data were available for obtaining clinically meaningful information for the primary efficacy endpoint of time to disease progression

    Time frame: At the time of data cut-off for this trial, the median overall duration of follow-up was 441 days, with a total of 434 (73.9%) randomised patients, including 47 patients from Japanese centres having progressed.

Secondary outcomes

  1. Objective response rate (ORR)

    It is considered that these results indicate that adequate data were available for obtaining clinically meaningful information for the primary efficacy endpoint of time to disease progression

    Time frame: At the time of data cut-off for this trial, the median overall duration of follow-up was 441 days, with a total of 434 (73.9%) randomised patients, including 47 patients from Japanese centres having progressed.

  2. Duration of response (DoR)

    Time frame: At the time of data cut-off for this trial, the median overall duration of follow-up was 441 days, with a total of 434 (73.9%) randomised patients, including 47 patients from Japanese centres having progressed.

  3. Time to treatment failure (TTF)

    Time frame: At the time of data cut-off for this trial, the median overall duration of follow-up was 441 days, with a total of 434 (73.9%) randomised patients, including 47 patients from Japanese centres having progressed.

  4. Overall survival (OS)

    Time frame: At the time of data cut-off for this trial, the median overall duration of follow-up was 441 days, with a total of 434 (73.9%) randomised patients, including 47 patients from Japanese centres having progressed.

  5. Quality of Life (QOL) and Tolerability.

    Time frame: At the time of data cut-off for this trial, the median overall duration of follow-up was 441 days, with a total of 434 (73.9%) randomised patients, including 47 patients from Japanese centres having progressed.

07

Study locations

139 sites
  • Research Site
    Little Rock, Arkansas, United States
  • Research Site
    Fountain Valley, California, United States
  • Research Site
    La Jolla, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Venice, Florida, United States
  • Research Site
    Decatur, Georgia, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Mason City, Iowa, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Gloucester, Massachusetts, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Voorhees, New Jersey, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Meadowbrook, Pennsylvania, United States
  • Research Site
    Providence, Rhode Island, United States
  • Research Site
    Austin, Texas, United States
  • Research Site
    Galveston, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Temple, Texas, United States
  • Research Site
    Richmond, Virginia, United States
  • Research Site
    Lacey, Washington, United States
  • Research Site
    Seattle, Washington, United States
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Rosario, Argentina
  • Research Site
    Camperdown, Australia
  • Research Site
    Concord, Australia
  • Research Site
    Heidelburg, Australia
  • Research Site
    Melbourne, Australia
  • Research Site
    Salzburg, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Antwerpen, Belgium
  • Research Site
    Haine-Saint Paul, Belgium
  • Research Site
    Hasselt, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Belo Horizonte, Brazil
  • Research Site
    Goiania, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Penticton, British Columbia, Canada
  • Research Site
    Saint John, New Brunswick, Canada
  • Research Site
    Newmarket, Ontario, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Weston, Ontario, Canada
  • Research Site
    York, Ontario, Canada
  • Research Site
    Chicoutimi, Canada
  • Research Site
    Montreal, Canada
  • Research Site
    Kotka, Finland
  • Research Site
    Kuopio, Finland
  • Research Site
    Rovaniemi, Finland
  • Research Site
    Clermont Ferrand, France
  • Research Site
    Evreux, France
  • Research Site
    Lyon, France
  • Research Site
    Montpellier, France
  • Research Site
    Pierre-Benite, France
  • Research Site
    Rodez, France
  • Research Site
    Rouen, France
  • Research Site
    Tours, France
  • Research Site
    Frankfurt, Germany
  • Research Site
    Gottingen, Germany
  • Research Site
    Rostock, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Pécs, Hungary
  • Research Site
    Szolnok, Hungary
  • Research Site
    Székesfehérvár, Hungary
  • Research Site
    Dublin, Ireland
  • Research Site
    Ashkelon, Israel
  • Research Site
    Haifa, Israel
  • Research Site
    Bologna, Italy
  • Research Site
    Brescia, Italy
  • Research Site
    Forli, Italy
  • Research Site
    Genova, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Palermo, Italy
  • Research Site
    Perugia, Italy
  • Research Site
    Pisa, Italy
  • Research Site
    Reggio Calabria, Italy
  • Research Site
    Reggio Emilia, Italy
  • Research Site
    Rozzano, Italy
  • Research Site
    Sassari, Italy
  • Research Site
    Trieste, Italy
  • Research Site
    Amagasaki, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Kitakyusyu, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Matsuyama, Japan
  • Research Site
    Nagoya, Japan
  • Research Site
    Niigata, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Saitama, Japan
  • Research Site
    Sapporo, Japan
  • Research Site
    Suita, Japan
  • Research Site
    Tokyo, Japan
  • Research Site
    Guadalajara, Mexico
  • Research Site
    Mexico, D.F., Mexico
  • Research Site
    Den Haag, Netherlands

Showing the first 100 of 139 sites across 26 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1998, a primary completion of Mar 2007 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2005
First posted
Oct 19, 2005
Start
Nov 1998
Primary completionActual
Mar 2007
CompletionActual
Jan 2012
Last update
Jun 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00241449
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 19, 2005
Start date
Nov 1998
Primary completion
Mar 2007
Completion
Jan 2012
Last update
Jun 6, 2012

Study contacts

AstraZeneca Oncology Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion